Newcells Biotech Ltd Raises Funding to Revolutionize Drug Discovery and Development with Predictive In Vitro Models

Newcells Biotech Ltd is excited to announce a significant funding milestone, having successfully raised £5 million in Series A funding to further enhance its innovative drug discovery and development platform. This investment will allow the company to expand its capabilities in providing gold-standard in vitro models, tailored to meet the complex needs of therapy development in the pharmaceutical industry. With an emphasis on ensuring safety and efficacy, Newcells Biotech leverages industry-leading expertise and cutting-edge technologies to create reliable tissue model platforms for retina, kidney, and lung applications. This unique approach allows their predictive models to closely mimic in vivo physiology, substantially reducing the guesswork involved in drug development. The funding will be utilized to enhance their existing technology, support the development of new predictive models, and boost their customer outreach to ensure that biopharmaceutical companies can effectively navigate the complexities of drug development. By providing intelligent preclinical models that deliver reliable data, Newcells Biotech is committed to helping its partners identify, avoid, and mitigate risks, ultimately increasing the chances of clinical success. In a sector where time-to-market can be critical, the company’s focus on predictive data aims to save money, time, and most importantly, lives. With this new capital injection, Newcells Biotech is poised to accelerate its growth and continue its mission to make a significant impact on the future of drug development.